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ABSTRACT
OBJECTIVE: To analyze the regional allocation of the resources from the Brazilian Popular 
Pharmacy Program, taking into account the relative availability of the program and the potential 
needs of the region. 
METHODS: Data from the National Health Survey of the Annual Report of Social Information 
and the administrative database of the program were used to create a non-parametric indicator 
of coverage using multiple data envelopment analysis technique. This indicator considers the 
relative availability of the program, taking into account equal access to equal needs (equity 
based on regional needs). The analysis of this indicator shows if the regions that most need 
pharmaceutical assistance are those that receive more resources from the Brazilian Popular 
Pharmacy Program.
RESULTS: The states belonging to the richest regions of the country, Southeast and South, 
present wider relative coverage of the Brazilian Popular Pharmacy Program compared to 
poorer localities. In addition, the inequalities observed between locations are better explained 
by inefficiency in the transfer of resources to the basic component of pharmaceutical care than 
by the Brazilian Popular Pharmacy Program itself. According to the model, a 43.76% increase 
in the transfer to the basic component of pharmaceutical care would be required in order to 
improve equity, whereas the increase required by the Brazilian Popular Pharmacy Program is 
equivalent to 22.71%.
CONCLUSIONS: Although the Brazilian Popular Pharmacy Program seeks to reduce the 
socioeconomic inequalities observed in access to pharmaceutical care, which integrates health 
care services, regional disparities in access to medicine persist. These regional differences 
are attributed mostly to allocation failures and problems in managing the conventional 
pharmaceutical care cycle provided through SUS pharmacies.
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INTRODUCTION
Chronic Noncommunicable Diseases (NCDs) are the leading causes of death in Brazil. The 
high prevalence of hypertension (15.6% of adults or 31.3 million people), diabetes (4.7% of 
adults or 9.5 million people) and asthma (4.4% of adults or 6.4 million) corresponds to a 
significant number of early deaths and loss of quality of life due to disability. These require 
follow-up with high complexity health care services and continuous pharmacological 
treatment, which represent a significant economic impact for society and for the patients 
themselves, requiring coping policies1–3.
According to data from the Family Budget Survey (POF) 2008-2009, medicine expenses 
corresponds to the largest share of family health expenses, especially for the poorest 
families4,5. For them, this expense accounted for 66% of health expenses, whereas in the 
richest families it accounted for 29%. Thus, family expenses on medicine in Brazil are 
regressive. This context makes it necessary to implement pharmaceutical assistance 
policies (PA) that can ensure the population’s access to pharmacological treatment, 
especially the continuum. One of the main causes of discontinuation of this type of 
treatment is family budget constraints, which can aggravate the patient’s condition 
and increase the public health system’s expenses with the provision of medical and 
hospital services6–8.
Given the difficulties families have to afford medicine, the federal government instituted the 
Brazilian Popular Pharmacy Program (BPPP). The program aims to ensure low-cost access 
to drugs considered indispensable for aggravations of wide prevalence in the population, 
whose treatment has a significant impact on the family budget, seeking to promote the 
integrity of health care and welfare gains9. Following the suspension of Rede Própria (RP) in 
2017, the program started to operate as Aqui Tem Farmácia Popular (ATFP), , also known as a 
network agreement (NA), which consists of a public-private partnership between the federal 
government and the private network of pharmacies and drugstores. It was implemented in 
2006, with the objective of expanding the program’s spatial coverage by using the existing 
structure of pharmaceutical retail.
However, the growing demand for health services coexists with the budget constraint and, 
inevitably, with the proposal to provide everything to everyone runs into the problem of 
limiting public resources10. Given the incompatibility between demand and public service 
offer, the national health policy is guided by the principle of equity in the provision of 
services to the population. Considering the importance of expanding drug access in the 
country, we analyze the regional allocation of BPPP resources, taking into account their 
relative availability and the potential needs of each region.
METHODS
A cross-sectional study was carried out to identify the allocation of public resources 
directed towards the pharmaceutical assistance system passed onto the Brazilian 
states and the Federal District, taking into account the concept of equity and using an 
extension of the Data Envelopment Analysis (DEA) model, called analysis Multiple Data 
Envelopment Analysis (MDEA). This study follows the definition of equity proposed 
by the National Health Policy for guiding the actions developed by the Unified Health 
System (SUS), according to which care for individuals should be provided according to 
their needs, offering more to those who need more, and less to those who require less. 
Thus, by considering different living and health conditions, it seeks to meet the needs of 
different social groupsa. 
The DEA technique is an instrument for determining the relative efficiency of a 
decision-making unit (DMU), based on the approximation of an efficiency frontier built 
according to the comparison of the resources employed and the results obtained in a 
a Fundação Oswaldo Cruz (BR). 
Pense SUS: equidade. Rio de 
Janeiro; s.d. [cited 2018 Jan 26]. 
Available from: https://pensesus.
fiocruz.br/equidade
3Equity of Popular Pharmacy resources Silva MEL et al.
https://doi.org/10.11606/S1518-8787.2019053000731
productive process. In this way, one can observe the units that present the best technologies 
in a given sample set. The efficiency points are those located on that border, whereas the 
DMUs below them are classified as inefficient11.
The empirical approach of this work was conceived considering the principles and directives 
of the National Health Policy of which the BPPP is part of, whose objective is to promote the 
balance among the benefited entities. In this sense, this evaluation follows the Puig-Junoy 
methodology12, which applies the DEA model to construct an equity indicator that matches 
local demands (needs) with the total value of the resources available for the service offering, 
taking into account the development of a border that indicates the maximum allocation of 
public services available to locations with similar needs.
The equity index (EI) obtained measures the relative deficit in service coverage provided 
by the distance between the observed point and the equity limit, indicating the inequality 
in the supply of services between locations with an array of similar needs. The locations 
below the equity limit have a deficit relative to the amount provided by the BPPP. In turn, 
the observations on this frontier are called equitable points from the perspective of the 
regional needs addressed.
For the implementation of the DEA approach, the productive units considered were the 
26 Brazilian states and the Federal District. Given the limited number of observations and 
the relatively large number of input and output variables, equity estimates were obtained 
according to the extension method MDEA13,14.
The MDEA was proposed to overcome the problem of sample dimensionality, when many 
DMUs are arbitrarily identified as equitable. By this approach, it is possible to correct 
potential classification errors in the DMUs, increasing the discriminatory power of the 
method15. The MDEA technique computes the EI by applying the DEA for all possible 
combinations of input-output subsets for each DMU, making the comparison between the 
federative units fairer. Based on the frequency distribution of the calculated EIs for each 
sample unit, the mean can be acquired and used to identify and order the level of regional 
equity for the provision of AF15.
In order to compose the vector for MDEA needs, data about the level of income, proportion 
of older people and prevalence of CNCDs (hypertension, diabetes and asthma) were 
collected. The variables income and older people were chosen because they characterize 
a social dimension measurement that considers the issue of free or subsidized access to 
medicine. The measure of negative income was applied, since the BPPP aims to reduce the 
impact of drug costs on the domestic budget, a way to achieve a better distribution of public 
resources, so that relatively more financially vulnerable states receive more resources than 
more developed sites. The variables of the service vector were the value transferred to the 
drugstores registered in the ATFP and the amount transferred to the basic component of 
pharmaceutical assistance (BCPA)b. 
The reference year of the study was established according to data from the National Health 
Survey (PNS) conducted in 2013 over the epidemiological profile related to CNCDs and the 
habits and living conditions of the Brazilian population, as well as access to and use of 
health services. In addition, data from the administrative and financial base of the BPPP 
and the Strategic Management Support Room of the Ministry of Health (SAGE/MS)c were 
used; the information regarding the number of drugstores by state was obtained in the 
Annual Social Information Report (RAIS)d. Table 1 presents the set of variables selected to 
estimate the EI and the descriptive statistics of the services vector in millions and of needs 
in thousands, paired with the variable tax income.
According to Table 1, in the year 2013, the average volume of direct transfers transferred 
by the state to pharmacies in the CR modality of the PFPB was approximately 67.5 
million reais, compared to approximately 38 million transferred to the CBAF. Analysis 
of the target diseases in this program shows that hypertension accounts for the 
b The basic component of 
pharmaceutical assistance is 
related to the acquisition of 
medicine and supplies from the 
National Relation of Essential 
Medicine (RENAME), within 
the scope of Primary Health 
Care carried out by the Unified 
Health System (SUS). Ministério 
da Saúde (BR). Assistência 
Farmacêutica: Relação Nacional 
de Medicamentos Essenciais 
(Rename). Brasília, DF; s.d. 
[cited 2018 Jan 26]. Available 
from: http://portalms.saude.gov.
br/assistencia-farmaceutica/
medicamentos-rename/
componente-basico-da-
assistencia-farmaceutica-cbaf
c Ministério da Saúde (BR). Sala 
de Apoio à Gestão Estratégica 
[homepage]. Brasília, DF; s.d. 
[cited 2018 Jan 26]. Available 
from: http://sage.saude.gov.br/
d Ministério do Trabalho (BR). 
Relação Anual de Informações 
Sociais -RAIS. Brasília, DF; 2017 
[cited 2017 Oct 10]. Available 
from: http://www.rais.gov.br/sitio/
tabelas.jsf
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highest proportion of chronic disease cases, with over one million diagnoses recorded, 
followed by diabetes and asthma, accounting for more than 300 and 200 thousand 
cases on average, respectively. The standard deviation shows great variability in the 
data, indicating that among the states there are favorable situations that coexist with 
significant deficiencies.
As this study aims to obtain the best availability of services within the same set of needs, 
the model was product-oriented so that service allocation was adjusted to meet local 
deficiencies. For the model estimation, the hypothesis of variable returns to scale (DEA-RSV) 
was assumed, considering the significant differences of socioeconomic factors and size of 
the federative units. 
RESULTS
Table 2 presents the EI calculated according to the MDEA for the 26 Brazilian states and 
the Federal District. A significant regional segregation of coverage indices is observed, 
wherein states belonging to the richest regions, South and Southeast, have better equity 
indices than the states of the North, Northeast and Midwest regions. Only one unit, the 
state of São Paulo, remained on the equity limit. The states with the lowest coverage 
are concentrated in the Northeast region, with Piauí having the highest relative deficit. 
However, the intersection between the Piauí, Pernambuco, Sergipe, Alagoas, Maranhão 
and Ceará confidence intervals is evident, demonstrating a homogeneity in fundraising 
between them. 
Given the inequality in the transfer of financial resources to the BPPP and the BCPA, Table 3 
presents a comparison between the effective amount paid to the federative units and the 
optimal amount that should be transferred, in millions, so that they can reach the border 
of equity, under a scenario without budget constraints.
The amount effectively transferred to the SUS pharmaceutical assistance corresponds to 
just over half of the transfers made to the BPPP. According to estimates computed by the 
MDEA, the increase in the amount passed to the BCPA required in order for all states to 
reach the equity limit would be 46.71%, whereas the BPPP would require 22.71%. The most 
significant differences between the effective value and the projected value of the BPPP are 
observed between the states of Amapá, Acre, Amazonas, Roraima and Tocantins, which 
receive only 1.1%, 3%, 5.8%, 13.8% and 27.6% of the optimal value, respectively. With regard 
to the BCPA, the data show the under-financing of the SUS’s PA system, especially in the 
cases of Amapá, Acre, Amazonas, Roraima and Tocantins, which should have increased 
Table 1. Presentation and descriptive statistics of the selected variables for estimating the equity index 
per Brazilian state, 2013.
Variable Mean Standard Deviation
Needs
Hypertension (thousands of people) 1.2 1.6
Diabetics (thousands of people) 337.84 506.9
Asthmatics (thousands of people) 238.44 333.2
Elderly (thousands of people) 978.07 1.4
Negative income (tax) 0.5351 0.7119
Services
BPPP value (millions of reais) 67.6 100.2
CBAF value (millions of reais) 38 44.33
BPPP: Brazilian Popular Pharmacy Program; BCPA: Basic Component of Pharmaceutical Assistance
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their resources by 98.9%, 97.1%, 94.2%, 86.2% and 72.6%, respectively, in order to reach 
optimal allocation.
However, the results do not imply an increase in resources allocated to the BPPP or the 
BCPA. Table 4 shows the increase required for the amount passed onto both pharmaceutical 
assistance systems, in millions, so that locations with relative coverage deficits can achieve 
optimal allocation by reallocating resources already available for the aforementioned 
programs between the federative units and the Federal District. Therefore, this table presents 
the values to be transferred to the BPPP and the BCPA for each location, according to the 
equity criterion, under a scenario with budget constraint. In this case two hypotheses were 
considered for evaluate this transfer.
The first investigates the allocation of financial resources by considering the programs 
complementary, since the federal government needs to finance distinct ways of dispensing 
Table 2. Equity index, standard error and confidence interval, 2013.
Major regions/states Equity Index Standard error CI95%
North 0.7837* 0.0352* 0.7147-0.8527*
Tocantins 0.6788 0.0281 0.6237–0.7338
Acre 0.7411 0.0407 0.6613–0.821
Amazonas 0.7512 0.0418 0.6692–0.8332
Pará 0.753 0.0326 0.6892–0.8169
Amapá 0.7587 0.0396 0.6811–0.8364
Rondônia 0.8348 0.0227 0.7903–0.8792
Roraima 0.968 0.0183 0.9322–1.0038
Northeast 0.7289* 0.0283* 0.6735–0.7843*
Piauí 0.6197 0.023 0.5747–0.6647
Pernambuco 0.657 0.0255 0.6069–0.7071
Sergipe 0.6808 0.0302 0.6216–0.7399
Alagoas 0.6969 0.0299 0.6383–0.7555
Maranhão 0.697 0.0376 0.6233–0.7706
Ceará 0.702 0.0295 0.6443–0.7598
Bahia 0.8142 0.0322 0.7511–0.8774
Rio Grande do Norte 0.8295 0.0184 0.7935-0.8654
Paraíba 0.8629 0.0206 0.8225–0.9032
Southeast 0.928* 0.0382* 0.8531–1.003*
Espírito Santo 0.8319 0.0225 0.7879–0.876
Rio de Janeiro 0.9024 0.0114 0.88–0.9248
Minas Gerais 0.9778 0.0072 0.9637–0.9918
São Paulo 1 0 1.00–1.00
South 0.9054* 0.0426* 0.7808–0.9479*
Santa Catarina 0.8733 0.0186 0.8368–0.9097
Paraná 0.9162 0.0149 0.887–0.9454
Rio Grande do Sul 0.9267 0.0151 0.8971–0.9563
Midwest 0.7889* 0.0512* 0.7046–0.9051*
Mato Grosso 0.7128 0.0263 0.6613–0.7643
Mato Grosso do Sul 0.7412 0.0237 0.6947–0.7876
Distrito Federal 0.812 0.0241 0.7649–0.8592
Goiás 0.8896 0.0175 0.8553–0.9239
* Average values by region.
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subsidized drugs to the population; thus, PA programs act as competitors and require 
specific budgets. The second considers the programs as mutually exclusive, as there is a 
superposition of the amount of medicine distributed by them. Hence, a single budget would 
be considered for both PA public policies.
According to the first hypothesis, it can be seen in Table 4 that the transfer directed to 
BPPP is higher than the amount directed to BCPA, with the exception of the North region. 
According to the second hypothesis, in which case the BPPP serves to supplement BCPA’s 
deficiencies, the budget directed to BCPA overcomes the transfer values for BPPP only at 
the North and Northeast regions. In the case of the Southeast, South and Midwest regions, 
the situation is similar to that described by the first hypothesis: the transfers directed to 
BPPP overcome the values for BCPA.
Table 3. Effective and projected values (in millions of reais) for BPPP and BCPA, under a scenario without budget constraint, 2013.
Major regions/states
Effective value Projected value
BPPP BCPA Total BPPP BCPA Total
North 44.76* 86.11* 130.87* 141.51* 605.46* 746.97*
Tocantins 5.1 8.19 13.29 18.51 25.05 43.56
Acre 0.29 4.04 4.33 9.87 78.2 88.07
Amazonas 0.98 18.47 19.45 17 222.3 239.3
Pará 25.63 41.2 66.83 50.13 76.05 126.18
Amapá 0.11 3.49 3.6 9.75 172.77 182.52
Rondônia 11.05 8.3 19.35 24.62 17.64 42.26
Roraima 1.6 2.42 4.02 11.63 13.45 25.08
Northeast 247.36* 292.64* 540* 477.51* 569.19* 1,046.7*
Piauí 13.73 16.69 30.42 34.12 38.56 72.68
Pernambuco 49.24 47.32 96.56 94.52 88.73 183.25
Sergipe 6.68 11.02 17.7 21.6 30.88 52.48
Alagoas 10.82 17.64 28.46 28.24 41.37 69.61
Maranhão 12.64 34.21 46.85 37.77 89.54 127.31
Ceará 36.64 47.58 84.22 71.63 89.29 160.92
Bahia 51.3 77.59 128.89 89.21 129.96 219.17
Rio Grande do Norte 35 18.91 53.91 53.26 28.84 82.1
Paraíba 31.31 21.68 52.99 47.16 32.02 79.18
Southeast 961.16* 424.44* 1,385.6* 1,024.36* 450.09* 1,474.45*
Espírito Santo 52.5 18.66 71.16 77.58 28.45 106.03
Rio de Janeiro 219.59 84.35 303.94 248.63 96.15 344.78
Minas Gerais 291.85 104.77 396.62 300.93 108.83 409.76
São Paulo 397.22 216.66 613.88 397.22 216.66 613.88
South 426.96* 146.81* 573.77* 496.66* 174.92* 671.58*
Santa Catarina 75.05 32.93 107.98 96.82 42.94 139.76
Paraná 130.81 56.62 187.43 150.55 65.65 216.2
Rio Grande do Sul 221.1 57.26 278.36 249.29 66.33 315.62
Midwest 144.1* 76* 220.1* 220.26* 125.6* 345.86*
Mato Grosso 15.8 17.09 32.89 34.37 34.78 69.15
Mato Grosso do Sul 16.43 13.25 29.68 33.82 26.16 59.98
Distrito Federal 24.03 13.49 37.52 42.35 23.71 66.06
Goiás 87.84 32.17 120.01 109.72 40.95 150.67
Total 1,824.34 1,026.00 2,850.00 2,360.30 1,925.26 4,285.56
BPPP: Brazilian Popular Pharmacy Program; BCPA: Basic Component of Pharmaceutical Assistance 
* Total amount per region.
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The results generally demonstrate the prioritization of resources for BPPP. It can be 
observed that the expansion of the program is associated to socioeconomical factors in 
such a way that macro-regions with higher income end up having higher coverage. This 
relationship can be simplified by the Figure with the dispersion diagram generated by 
the estimated regression between the relative coverage deficit (complement of the equity 
index) and the ratio of accredited pharmacies in the NA modality of BPPP. Among the 
states from the South and Southeast regions, there is a high degree of adherence by private 
establishments to the agreed area, whereas the states of the North and Northeast regions 
face a high relative coverage deficit. The Midwest on the other hand is characterized as 
an intermediate scenario.
Table 4. Equity coefficient and projected values (in millions of reais) for BPPP and BCPA, under a budget constraint scenario according to 
type of relationship between programs, 2013.
Major regions/states 
Complementary Substitution
Coef. BPPP Coef. BCPA BPPP value BCPA value Coef. BPPP Coef. BCPA BPPP value BCPA value
North 109.38* 322.68* 94.11* 402.7*
Tocantins 0.008 0.013 14.31 13.35 0.004 0.006 12.31 16.66
Acre 0.004 0.041 7.63 41.68 0.002 0.018 6.57 52.01
Amazonas 0.007 0.116 13.14 118.47 0.004 0.052 11.3 147.86
Pará 0.021 0.04 38.75 40.53 0.012 0.018 33.34 50.58
Amapá 0.004 0.09 7.53 92.08 0.002 0.04 6.48 114.91
Rondônia 0.01 0.009 19.03 9.4 0.006 0.004 16.37 11.73
Roraima 0.005 0.007 8.99 7.17 0.003 0.003 7.74 8.95
Northeast 369.07* 303.35* 317.58* 378.59*
Piauí 0.015 0.02 26.37 20.55 0.008 0.009 22.7 25.65
Pernambuco 0.04 0.046 73.06 47.29 0.022 0.021 62.87 59.02
Sergipe 0.009 0.016 16.69 16.46 0.005 0.007 14.36 20.54
Alagoas 0.012 0.022 21.83 22.05 0.007 0.01 18.78 27.52
Maranhão 0.016 0.047 29.2 47.72 0.009 0.021 25.12 59.55
Ceará 0.03 0.046 55.36 47.58 0.017 0.021 47.64 59.39
Bahia 0.038 0.068 68.95 69.26 0.021 0.03 59.33 86.44
Rio Grande do Norte 0.023 0.015 41.16 15.37 0.012 0.007 35.42 19.18
Paraíba 0.02 0.017 36.45 17.07 0.011 0.008 31.36 21.3
Southeast 791.77* 239.87* 681.33* 299.37*
Espírito Santo 0.033 0.015 59.96 15.16 0.018 0.007 51.6 18.92
Rio de Janeiro 0.105 0.05 192.18 51.24 0.058 0.022 165.37 63.95
Minas Gerais 0.128 0.057 232.6 58 0.07 0.025 200.16 72.39
São Paulo 0.168 0.113 307.03 115.47 0.093 0.051 264.2 144.11
South 266.04* 80.75* 330.34* 116.34*
Santa Catarina 0.041 0.022 74.84 22.88 0.023 0.01 64.4 28.56
Paraná 0.064 0.034 116.36 34.99 0.035 0.015 100.13 43.66
Rio Grande do Sul 0.106 0.035 196.69 35.35 0.058 0.016 165.81 44.12
Midwest 170.25* 66.93* 146.49* 83.54*
Mato Grosso 0.015 0.018 26.57 18.53 0.008 0.008 22.86 23.13
Mato Grosso do Sul 0.014 0.014 26.14 13.94 0.008 0.006 22.49 17.4
Distrito Federal 0.018 0.012 32.74 12.64 0.01 0.006 28.17 15.77
Goiás 0.047 0.021 84.8 21.82 0.026 0.01 72.97 27.24
Total 1,706.51 1,013.58 1,569.85 1,280.54
BPPP: Brazilian Popular Pharmacy Program; BCPA: Basic Component of Pharmaceutical Assistance; Coef.: coefficient 
* Total amount per region.
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DISCUSSION
Based on the equity criterion, this study evaluated the performance of the BPPP in meeting 
the pharmacological needs of the population through a comparative analysis between 
states. It can be seen that the equity indicators reflect regional inequalities, wherein states 
located in the richest regions are more assisted by the BPPP than the states from the poorest 
regions, North and Northeast.
In view of the presented scenario, the factors that can explain these regional inequalities 
are socioeconomic aspects or differences in the capture of resources transferred to the 
BPPP and the BCPA. This may signal problems in the management of pharmaceutical care 
provided by pharmacies in the public health system.
Considering that the states with the best equity rates are found in the richest regions of 
the country16, it can be verified that the territorial expansion of the program responds 
to commercial factors, to the detriment of the equity criterion, one of the principles that 
guide national healthcare policy actions. This can be attributed to the socioeconomic 
characteristics of the regions, due to the absence of initial criteria to guide the 
implementation of units from the agreed area. In this way, the expansion and distribution 
of medicine occurs due to the voluntary decision of private establishments to participate in 
the program. According to this hypothesis, drugstores located in more developed regions 
TO: Tocantins; AC: Acre; AM: Amazonas; PA: Pará; AP: Amapá; RO: Rondônia; RR: Roraima; PI: Piauí; 
PE: Pernambuco; SE: Sergipe; AL: Alagoas; MA: Maranhão; CE: Ceará; BA: Bahia; RN: Rio Grande do Norte; 
PB: Paraíba; ES: Espírito Santo; RJ: Rio de Janeiro; MG: Minas Gerais; SP: São Paulo; SC: Santa Catarina; 
PR: Paraná; RS: Rio Grande do Sul; MT: Mato Grosso; MS: Mato Grosso do Sul; DF: Distrito Federal; GO: Goiás
Figure. Dispersion diagram of the coverage deficit versus the proportion of drugstores registered in the 
program Aqui Tem Farmácia Popular (ATFP)  per Brazilian state, 2013.
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with a higher potential audience for the diseases covered by the program are more likely 
to participate in it17.
The regions that meet these conditions are the South and Southeast, which present a 
higher proportion of older people, better income indicators and lower inequality, ranking 
better than other regions with regard to the main factors pointed out in the literature as 
constituting barriers to medicine access18. On the other hand, the North and Northeast 
regions have less potential for consumption, both because they have lower income 
available to be spent on medicine and non-medicine products, and because they are 
still at the beginning of the aging population process. Thus, the incidence of CNCDs, 
more common with advanced age, is less observed in these localities than in the South 
and Southeast of the country. The association between these factors represents a lower 
demand for products commercialized in the pharmaceutical sector, which discourages 
drugstores from joining the ATFP. Hence why the BCPA has a greater projection in the 
North and Northeast regions, since the market in these localities is less attractive to the 
pharmaceutical retail sector, with it being incumbent on SUS pharmacies to promote 
the access to medicine.
However, when observing the performance of the states in providing the PA system 
in both alternatives, the BPPP is evidently beneficial to the detriment of the SUS PA 
system, as can be verified in the literature on the subject. Specifically, the results denote 
the insufficiency of the BCPA resources as the main cause of inefficiency in North and 
Northeast locations, such as Amapá, Amazonas and Bahia. Compared to the other regions, 
the greatest adjustment occurs for the resources destined to the BPPP. Therefore, under-
financing and a possible mismanagement of the resources allocated to the public PA 
system can be verified. This result provides empirical evidence and corroborates with the 
hypotheses constructed by Santos-Pinto et al.10 The authors, observing the high demand 
of BPPP by SUS users, affirm that this migration process in the search for pharmacological 
treatment can signal failures and inefficiency in the performance of SUS managers and 
local professionals in the pharmaceutical assistance cycle. In such cases, the BPPP is 
not in accordance with its role as an alternative for access to medicine, but represents 
the main access route to pharmacotherapy, even for those who depend on the public 
provision of medicine19.
This situation indicates that the beneficiaries who should acquire the medicine for free buy 
it through direct disbursement. The data analyzed do not only refer to the purchase of drugs 
prescribed for the treatment of hypertension, diabetes and asthma, which are exempt from 
co-payment, but also include transfers for the treatment of osteoporosis, rhinitis, Parkinson’s 
and glaucoma, which still require co-payment. In extreme cases occur the highest income 
compromise possible, stimulating the discontinuation of the drug regimen, associated with 
the worsening of the patient’s health condition. Hence, in some cases, the requirement of 
the co-payment rate may represent a cost higher than the families’ ability to pay, making 
it impossible for them to be served by the program20,21.
Despite a high rate of adherence to the program by pharmacies located in the South and 
Southeast regions, the results show that the national average participation of pharmaceutical 
units is low: 43% of private pharmacies are ATFP-enabled, so only 10% of the drug market 
is covered by it22. Due to the characteristics of the NA, the program’s most expressive part, 
the low adherence of businessmen in the sector restricts their geographical insertion, which 
implies the persistence of barriers that limit access to medicine in the country. It is therefore 
necessary for the federal government to adopt measures that promote the sustainability of 
the program by stimulating the participation of private drugstores, in order to guarantee the 
integral treatment of CNCDs and, thus, promote the efficiency of the health care system in 
the country23. From the perspective of the entrepreneur, given the complex market structure 
of pharmaceutical retail24, adherence to the program may represent a dissemination and 
demand increase strategy, increasing the profitability of accredited establishments. Hence, 
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incentives granted by the federal government to pharmacies in order to participate in the 
ATFP may have benefits for society, businesses and the government.
It can be concluded that there are still barriers to medicine access in the country, especially 
in the regions that are poor and dependent on the public health system. The unavailability 
of medication makes it impossible to effectively adhere to pharmacotherapy, bringing 
complications associated with diseases that are out of control and generating additional 
costs for the public health sector. Given that the decline in quality of life and well-being 
compromise productivity and human capital accumulation, the reaffirmation of public 
policies that promote the expansion of health care services, including pharmaceutical 
assistance, is a factor that drives socioeconomic development in the locations served.
Finally, as this study used cross-sectional data, the results presented should be 
interpreted with caution, taking into account possible noises25. However, these results 
can be instruments to subsidize the elaboration of health policies that favor the efficient 
allocation of resources, in order to comply with the principles and guidelines defined by 
the national health policy, aiming for the social well-being and sustainability of public 
health financing.
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